HTGF et al. back Cysal

The deal was valued in the €1-9m range. Both investors contributed equal amounts of funding to the round.

The company will use the fresh capital to accelerate product development and facilitate market entry, in cooperation with a service provider. Cysal plans to set up its own production capacities at the Technology Park in Münster in the near future.

Company
Cysal was founded in June 2012 by Dr Ahmed Sallam and Oxford University's Dr Martin Krehenbrink. The company is a spin-off from the Institute for Molecular Microbiology and Biotechnology at the Westphalian Wilhelms-University in Münster.

Cysal has developed a way of producing dipeptides, a combination of two amino acids, cheaply and on an industrial scale. It uses the compounds as base material for the manufacture of finished products developed in-house such as energy tonics, skin creams, fish feed additives, and infusions.

People
Matthias Dill is an investment manager at HTGF and Marcel Vonnahme is an investment manager at eCapital.

Advisers
Equity – Ralf Hoffmann (Legal).

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany
• High-Tech Gründerfonds